Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...
This week, a new paper described how researchers pieced together the entire molecular structure of the protein shell of the HIV virus using GPU-based simulations. This remarkable achievement not only ...
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...
As the HIV virus glides up outside a human cell to dock and possibly inject its deadly cargo of genetic code, there's a spectacularly brief moment in which a tiny piece of its surface snaps open to ...
Seeing a glycoprotein on the envelope of the HIV virus snap open and shut in mere millionths of a second is giving investigators a new handle on the surface of the virus that could lead to broadly ...
Duke Human Vaccine Institute (DHVI) investigators used a technique called time-resolved, temperature-jump (TR, T-Jump) small-angle x-ray scattering (SAXS) to capture the spectacularly brief moment ...
Left: Structure of the Human Immunodeficiency Virus (HIV). Note the envelope protein that protects the virus against immunological detection and the small genome consisting of two short strands of RNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results